natgillin/translations-raw huggingface dataset:
The residue is dissolved in ethyl acetate (30 ml) and washed with saturated sodium hydrogencarbonate solution. 
Ostatak se otopi u etil acetatu (30 ml) i ispere sa zasičenom otopinom natrijevog hidrogenkarbonata.
The compound for use according to claim 10 wherein at least one of the additional compounds is selected from interleukin 2, interleukin 6, interleukin 12, a compound that enhances the development of a type I helper T cell response, interfering RNA, anti-sense RNA, Imiquimod, ribavirin, an inosine 5'-monophospate dehydrogenase inhibitor, amantadine, and rimantadine. 
Spoj za uporabu prema zahtjevu 10 gdje se barem jedan od dodatnih spojeva izabire između interleukina 2, interleukina 6, interleukina 12, 1 spoja koji pojačava nastanak odgovora pomoćnih T stanica tipa 1, interferirajuće RNA, anti-sense RNA, Imikvimoda, ribavirina, inhibitora inozin 5'-monofosfat dehidrogenaze, amantadina i rimantađina.
The ozone sanitizing system of claim 1, further comprising a timer connected to the ozone operating system to control the operation of the ozone operating system and, more specifically, the release of ozone into the water reservoir. 
Uređaj CPAP (105) u skladu s patentnim zahtjevom 1, naznačen time što dodatno ima mjerač vremena ugrađen u ozonski uređaj (100) radu upravljanja radom sustava za rad s ozonom (115) i, specifičnije, otpuštanja ozona u uređaj CPAP (105).
To the residue was slowly added ice (250 gm) followed by the slow addition of water (250 ml). 
Ostatku je polagano dodan led (250 mg) nakon čega je uslijedio polagani dodatak vode (250 mL).
—S(—O-dodecanoyl) means a serine, the hydroxyl group of which is substituted by a dodecanoyl group. 
S(O-dodekanoil) predstavlja serin, čija je hidroksilna skupina supstituirana s dodekanoil skupinom.
-OR8, -OCOR8, wherein R8 is selected from hydrogen, substituted or unsubstituted lower alkyl, substituted or unsubstituted lower alkenyl, substituted or unsubstituted lower alkynyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl 
-OR8, -OCOR8, gdje R8 je izabran iz grupe koju čine vodik, supstituiran ili nesupstituiran niži alkil, supstituiran ili nesupstituiran niži alkenil, supstituiran ili nesupstituiran niži alkinil, supstituiran ili nesupstituiran aril, supstituiran ili nesupstituiran heteroaril
The vaccine of claim 1 or 2, wherein the recombinant Mycobacterium bovis cell is characterized as rBCG AUrec:: Hly+:: Hyg+. 
Rekombinantna Mycobacterium bovis stanica iz zahtjeva 1 ili 2, koja je okarakterizirana kao rBCG AUrec:: Hly+:: Hyg+.
The process of any one of claims 2 to 6, wherein: said secondary amine is selected from the group consisting of piperidine, pyrrolidine, piperazine, dialkylamines, and diarylalkylamines, 
Postupak u skladu s patentnim zahtjevom 14, naznačen time što navedeni sekundarni amin se bira iz skupine koju čine piperidin, pirolidin, piperazin, dialkilamini i diarilalkilamini.
Aryl includes a ring system containing an optionally substituted 6-membered carbocyclic aromatic ring, said system may be bicyclic, bridge, and/or fused. 
Aril uključuje prstenasti sustav koji sadržava eventualno supstituirani 6-člani karbociklički aromatski prsten, pri čemu prstenasti sustav može biti biciklički, premošten i/ili spojen.
The antibody of claim 1 or claim 2, wherein said second polypeptide comprises a heavy chain having the amino acid sequence of SEQ ID NO: 9. 
Protutijelo prema zahtjevu 1 ili zahtjevu 2, naznačeno time da navedeni drugi polipeptid sadrži teški lanac koji ima sekvencu amino kiseline iz SEQ ID NO: 9.
This is especially important if the pressure in the pressure chamber 8 is high. 
Ovo je posebno važno ako je pritisak u tlačnoj komori 8 visok.
The peptide of claim 7, wherein the second amino acid from the N-terminus of the amino acid sequence of SEQ ID NO: 110, 111, 387, 112, or 394 is substituted with phenylalanine, tyrosine, methionine, or tryptophan. The peptide of claim 7 or 8, wherein the C-terminal amino acid of the amino acid sequence of SEQ ID NO: 110, 111, 387, 112, or 394 is substituted with phenylalanine, leucine, isoleucine, tryptophan, or methionine. The peptide of claim 6, wherein said peptide consists of the amino acid sequence of SEQ ID NO: 110, 111, 387, 112, or 394. 
Peptid od manje od 15 aminokiselina koji može inducirati citotoksičnu T-stanicu, naznačen time što navedeni peptid ima aminokiselinski slijed u kojem je druga aminokiselina od N-kraja u aminokiselinskom slijedu SEQ ID NO:41, 44, 46, 48 ili 78 zamijenjena fenilalaninom, tirozinom, metioninom ili triptofanom i/ili je C-terminalna aminokiselina u aminokiselinskom slijedu SEQ ID NO:41, 44, 46, 48 ili 78 zamijenjena fenilalaninom, leucinom, izoleucinom, triptofanom ili metioninom, gdje navedeni peptid inducira citotoksičnu T-stanicu specifičnu za stanicu koja eksprimira EphA4. Peptid u skladu s patentnim zahtjevom 6, naznačen time što navedeni peptid ima aminokiselinski slijed SEQ ID NO:41, 44, 46, 48 ili 78.
Through empirical testing or knowledge, the application amount from system 10 can be determined. 
Empirijskim probama ili znanjem, može se odrediti količina za nanošenje iz sustava 10.
A compound (VI) having the structure: wherein LG is a potential leaving group, e.g. 
Spoj (VI) sa strukturom: LG (vn gdje je LG moguća odlazna skupina, npr.
is H or F; and is H or CH3. A composition according to claim 1, wherein the compound is selected from compounds having Formula (IIe) and pharmaceutically acceptable salts, solvates, and hydrates thereof: wherein: 
R; je H ili CHi. . Pripravak u skladu sa zahtjevom 1, naznačen time, da je spoj izabran među spojevima koji imaju Formulu (Ile) i njihovim farmaceutski prihvatljivim solima, solvatima i hidratima: gdje:
The present invention also provides (A) and (B) as herein before defined in combination therapy by simultaneous, sequential, or separate administration in the treatment of respiratory diseases. 
Predmetni izum također daje (A) i (B) kako je ovdje prije definirano, u kombiniranoj terapiji kod istodobnog davanja, davanja jednog za drugim, ili zasebnog davanja, kod liječenja respiratornih bolesti.
Wind system (1) according to claim 1, characterised in that it comprises for each of said modules (5) a winding and unwinding system (22) of said rope (4). 
Vjetreni sustav (1) prema zahtjevu 2, naznačen time da se spomenuti spojler pokreće preko sustava sa samostalnim napajanjem.
As is known in the art, it is preferred that the individual emulsion droplets have a small and uniform size because these properties result in a more stable emulsion. 
Kao što je poznato u struci, poželjno je da pojedinačne kapljice emulzije imaju malu i jednoličnu veličinu, zato što ta svojstva rezultiraju stabilnijom emulzijom.
The starting materials for the process of step (a1) are tripeptides and tetrapeptides, optionally mono- or di-esterified, optionally protected at the glutamyl amine, and with the cysteine sulfur deprotected. 
Početni materijali za postupak (Â«sulfidni spoj Â«) su tripeptidi, po izboru mono- ili di- esterificirani, po izboru zaštićeni na glutamil aminu, i sa cistein sulfurom alkilirani sa Z-CH,- skupinom.
The method according to claim 1, wherein the at least one fiber-optic sensor unit has a converter structure which amplifies the shear deformation that acts on the at least one fiber-optic sensor unit. 
Primjena prema jednom od zahtjeva 1 do 6, pri čemu vlaknasto-optička senzorna jedinica (303; 330; 330a, 330b) ima strukturu konvertora, koja pojačava mehaničku varijablu koja djeluje na senzornu jedinicu (303; 330; 330a, 330b).
it comprises an increased amount of sialic acid compared to a protein composition of the same protein molecule when expressed in the cell line CHOdhfr− [ATCC No. 
- sadrži povećana količina sijalinske kiseline u usporedbi s proteinskim pripravkom s istom molekulom proteina kada se eksprimira u staničnoj liniji ATCC No.
The invention is also directed to a sustained release pharmaceutical composition comprising venlafaxine or a salt thereof, which composition can be in the form of coated pellets or capsules for once-a-day oral administration. 
Ovaj izum također se odnosi na farmaceutski pripravak s produljenim otpuštanjem koji sadrži venlafaksin ili njegovu sol, gdje navedeni pripravak može biti u obliku obloženih peleta ili kapsula namijenjenih za oralnu primjenu jednom dnevno.
Process of any of the claims 1 and 2 wherein the product obtained after step c) is purified. 
Proces prema bilo kojem od patentnih zahtjeva 1 12 pri čemu je proizvod dobiven nakon koraka e) pročišćen.
The present invention encompasses the use of compounds of the invention for reducing the insulin resistance and hyperglycemia in any or all of the above rodent diabetes models, in humans with type 2 diabetes or other preferred metabolic-related disorders or disorders of lipid metabolism described previously, or in models based on other mammals. 
Prikazani izum obuhvaća spojeve izuma za smanjenje inzulinske rezistencije i hiperglikemije u bilo kojem od gore navedenih modela dijabetesa glodavaca, kod ljudi s dijabetesom tipa 2 ili ostalim preferiranim metaboličkim poremećajima ili poremećajima metabolizma lipida opisanim ranije u tekstu, kao i kod modela na ostalim sisavcima.
The mouse of claim 6, wherein the four unrearranged human Jλ gene segments are Jλ1, Jλ2, Jλ3 and Jλ7. 
Miš prema zahtjevu 6, naznačen time, što četiri nepreuređena humana segmenta gena JA jesu JA1, JA2, J43 127.
Application of the deuterated benzopyran compounds, or pharmaceutically acceptable salts or stereoisomers thereof, or prodrug molecules thereof according to any one of claims 1 to 5 in preparing anti-inflammatory and analgesic drugs or preparing drugs for preventing or treating tumors. 
Deuterirani benzopiranski spoj ili farmaceutski prihvatljiva sol prema bilo kojem od prethodno navedenih patentnih zahtjeva za upotrebu u pripremi antiinflamatornih i analgetičkih lijekova ili pripremi lijekova za prevenciju ili liječenje tumora.
A method for blocking nonspecific binding of antibodies in an in vitro or ex vivo assay comprising incubating target tissue or target cells with a composition comprising an effective amount of the biomimetic compound of claim 4. 
7. = Postupak blokiranja nespecifičnog vezanja protutijela u testiranju in vitro ili ex vivo, naznačen time, da obuhvaća inkubaciju ciljanog tkiva ili ciljanih stanica sa sastavom koji obuhvaća učinkovitu količinu spoja biomimetika prema zahtjevu 4.
The intermediate was used without further purification or treatment. 
Intermedijer je uporabljen bez dodatnog pročišćavanja ili obrade.
anti-hypertensive agents, and 
anti-hipertenzijska sredstva,
antibody-like proteins; or peptidomimetics. The binding moiety of claim 11, wherein the binding moiety is an antibody or an antigen-binding fragment thereof, said antibody being selected from the group consisting of polyclonal antibodies, monoclonal antibodies, chimeric antibodies, humanized antibodies, and human antibodies. 
Vezujuća grupa prema bilo kojem od zahtjeva 1 do 4, pri čemu je vezujuća grupa antitijelo ili njegov antigen vezujući fragment, pri čemu je spomenuto antitijelo izabrano iz grupe koja se sastoji od poliklonskih antitijela, monoklonskih antitijela, kimeričnih antitijela, humaniziranih antitijela, i humanih antitijela.
An inclusion complex according to claim 3, wherein the cyclodextrin is 2-hydroxypropyl-B-cyclodextrin. 
Inkluzijski kompleks u skladu s patentnim zahtjevom 3, naznačen time, da je ciklodekstrin 2-hidroksipropil-B-ciklodekstrin.
The aqueous layer was washed with ethyl acetate (300 ml) and the organic solutions were combined. 
Vodeni sloj se pere etil acetatom (300 ml) i organske otopine se spoje.
Eventually, the capsule 1 will even automatically fall down from the bell element 9. 
Na kraju, čahura 1 će čak i automatski pasti dolje iz zvonastog elementa 9.
a demultiplexer circuit with more outputs). 
demultipleksnim komunikacijskim krugom s više izlaza).
The material for these seals can e.g. 
Materijal za te brtve može biti npr.
The antibody or antigen binding fragment of any one of claims 1 to 10, wherein the antibody or antigen binding fragment is an IgG2-A isoform or an IgG2-A/B isoform, but not an IgG2-B isoform. 
Protutijelo ili fragment koji veže antigen prema bilo kojem od patentnih zahtjeva 1 do 10, naznačeno time, da protutijelo ili fragment koji veže antigen je izoform IgG2-A ili izoform IgG2-A/B, ali nije izoform IgG2-B.
A problem with omeprazole is its stability characteristics. 
Problem s omeprazolom je u njegovim karakteristikama stabilnosti.
Oxidation of plasma lipoproteins was assessed as the capacity of oxidation of heparinized plasma and was measured by spectrophotometry as in increase in absorbance at 234 nm. 
Oksidacija lipoproteina plazme ispitana je kao sposobnost oksidacije heparinizirane plazme i izmjerena je spektrofotometrijom kao porast apsorpcije pri 234 nm.
It is an embodiment of the present invention that the combination, product, kit of parts or package comprises (b) an M3 antagonist of the invention and (a) a B2 agonist, as the sole active compounds. 
U jednom od utjelovljenja predmetnog izuma kombinacija, proizvod, pribor ili paket sadrže (b) M3 antagonist sukladno predmetnom izumu i (a) kortikosteroid, kao jedine djelatne spojeve.
an actuating device having an actuating element, to which the injection syringe can be coupled and which is adapted for actuation of the injection syringe for injecting an injectable substance into the organism, wherein 
- uređaj za pokretanje (20) koji se može spariti sa injekcijskom špricom (50) 1 koji je prilagođen za pokretanje te injekcijske šprice (50) za ubrizgavanje injekcijske supstance u organizam (1), naznačeno time da
It is further possible that the layer thickness of the first compensation layer is less than the layer thickness of the at least one first color layer, in particular that the layer thickness of the first compensation layer lies in the range of from 10% to 50% of the layer thickness of the at least one first color layer. 
Transferna folija (1) prema jednom od prethodnih patentnih zahtjeva, naznačena time, da je prvi kompenzacijski sloj (90) i/ili drugi kompenzacijski sloj transparentan i/ili bezbojan, i/ili je prvi kompenzacijski sloj (90) i/ili drugi kompenzacijski sloj oblikovan kao prianjajući sloj, osobito kao adhezivni sloj.
The use according to claim 10, wherein said composition is additionally combined with at least one further unit dose of said phosphorus compound binding agent to be immediately swallowed, consisting the two unit doses in at least one therapeutic unit. 
Primjena prema zahtjevu 10, naznačena time što je spomenuta smjesa dodatno kombinirana s najmanje još jednom pojedinačnom dozom spomenute tvari za vezanje fosfornog spoja koja se odmah guta, tako da se sastoji od dvije pojedinačne doze u najmanje jednom terapijskom obliku
The compound for use according to claim 6, wherein the inflammatory condition is inflammatory bowel disease. 
Sol spoja za uporabu prema patentnom zahtjevu 5, pri čemu je upalno stanje Kronova bolest.
Liquid receiving system according to claim 1, wherein the box shaped elements (39) have a parallelepiped shape. 
Sustav za prihvat tekućina u skladu s patentnim zahtjevom 1, naznačen time što kutijasti elementi (39) su u obliku kvadra.
The pharmaceutical composition of claim 1, wherein the inhibitor of NS5B polymerase is a non-nucleoside inhibitor. 
Farmaceutski sastav patentnog zahtjeva 4, gdje je navedeni terapeutski agens inhibitor NS5B polimeraze.
To 100 g of 6-fluoro-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid (IV), 1500 ml of methylene chloride and 70 g of triethylamine were added at 20° to 40° C. The reaction mixture was cooled to 0° to −5° C. and 57 g of ethylchloroformate was slowly added over a period of 30 to 45 minutes. 
U 100 g 6-fluoro-3,4-dihidro-2H-1-benzopiran-2-karboksilne kiseline (IV) dodano je 1500 ml metilen klorida 1 70 g trietilamina na 20-40 "C. Reakcijska smjesa je ohlađena na 0 *C do -5 "C te je polagano dodavano 57 g etilklorformata tijekom razdoblja od 30 do 45 minuta.
Also provided is a product comprising (a) a B2-agonist and (b) an M3 antagonist of the invention as a combined preparation for simultaneous, concurrent separate or sequential use in the treatment of a human or animal patient. 
Takoder je omogućen proizvod koji sadrži (a) kortikosteroid i (b) M3 antagonist sukladno predmetnom izumu u obliku kombiniranog pripravka za istovremenu, odvojenu ili sekvencijalnu uporabu u liječenju bolesnih ljudi ili životinja.
fluorine, phosphorus and magnesium and 
- > fosfor i magnezij i
Then it is stirred for 2 hours and 30 minutes at room temperature. 
Zatim se to miješa još 2 sata 1 30 minuta pri sobnoj temperaturi.
What the user is unaware of is that there is the intermediate position where both the inlet valve and the outlet valve are closed. 
Ono što korisnik ne zna je da se tu nalazi međupoložaj u kojem su oba ventila, ulazni i izlazni, zatvoreni.
A non-naturally occurring molecule comprising at least one B-aggregating region isolated from a protein domain capable of being soluble in water wherein said B-aggregating region is exposed to the environment and fused to a moiety that prevents aggregation of said beta-aggregating region, wherein said molecule is obtainable by providing 
Molekula koja se ne javlja u prirodi naznačena time da sadrži barem jedno B-agregacijsko područje koje je izolirano iz proteinske domene koja se može otopiti u vodi pri čemu je navedeno B-agregacijsko područje izloženo okolini i fuzionirano na skupinu koja sprječava agregaciju navedenog beta-agregacijskog područja, pri čemu se navedena molekula može dobiti tako da sadrži
The combination for use according to claim 1, for use in the treatment of type 1 or type 2 diabetes, the combination comprising: (i) glucokinase expression cassette configured to express a functional glucokinase protein in a pancreatic cell, (ii) a tyrosine phosphatase 1B inhibitor that is an shRNA inhibitor of protein tyrosine phosphatase 1B (PTP1B) or a PTPIB antisense DNA and (iii) a Pdx-1 expression cassette configured to express a functional Pdx-1 protein in a pancreatic cell, the combination being adapted to induce pancreatic beta cells in the pancreas. 
Kombinacija za uporabu prema zahtjevu 1, naznačena time da je za uporabu za liječenje dijabetesa tipa 1 ili tipa 2, te kombinacija sadrži: (1) kasetu za ekspresiju glukokinaze koja je konfigurirana da eksprimira funkcionalni protein glukokinaze u stanici gušterače, (ii) inhibitor tirozin fosfataze 1B koji je shRNA inhibitor proteina tirozin fosfataze 1B (PTPIB) ili PTPIB antisensna DNA i (iii) Pdx-1 ekspresijska kaseta je konfigurirana da eksprimira funkcionalni protein Pdx-1 u stanici gušterače, te je kombinacija prilagođena da inducira beta stanice gušterače u gušterači.
The present invention relates to the treatment of visceral pain including pancreatitis pain, labor pain, pain from abdominal surgery associated with ileus, pain in irritable bowel syndrome, abdominal pain in nonulcer dyspepsia, or in dysmenorrhea, liver pain, kidney pain, epigastric pain, pleural pain, and painful biliary colic and appendicitis pain by administering analgesic medications comprising the oxycodone alone or in combination with other active agents and especially other analgesics. 
Upotreba prema bilo kojem od prethodnih zahtjeva, naznačena time da je organska bol bol kod pankreatitisa, porođajna bol, bol nastala operacijom u području abdomena povezana s tankim crijevom, bol kod iritabilnog sindroma crijeva, abdominalna bol kod neulkusne dispepsije, ili kod dismenoreje, bol jetre, bol bubrega, bol u epigastriju, pleuralna bol, bolan bilijarni kolik ili bol kod apendicitisa.
aliquoting each of the plurality of samples into a well of a microtitre plate or microfuge tube; 
(ii) uzimanje alikvota svakog od množine uzoraka u jažice mikrotitracijske ploče ili mikrocentrifugalne epruvete;
What is more, owing to the non-detachable connection of the channel parts to the air-tight covering, an additional covering foil can be omitted and the air-tight covering with channel parts can be reused. 
K_ tome, zbog nerastavljivog spoja dijelova kanala s neprodušnim pokrovom, može se izostaviti dodatnu pokrovnu foliju, a neprodušan pokrov s dijelovima kanala može se ponovno upotrijebiti.
After 1 h the slurry was filtered and washed with 45 mL IPA (solids can also be washed with a water/IPA solution to avoid turnover to other crystal forms). 
Nakon 1 h smjesa je filtrirana i isprana sa 45 mL IPA (krutina može također biti isprana sa voda/IPA otopinom, da se izbjegne pojava formiranja drugih kristala).
Preferably, the at least one additional peptide has the amino acid sequence set forth in SEQ ID NO:2 to 19 and SEQ ID NO:21 to 26. 
Farmaceutski sastav prema zahtjevu 1, koji nadalje uključuje najmanje jedan dodatni peptid koji sadrži slijed aminokiselina odabranog iz skupine koja se sastoji od SEQ ID NO 1 te SEQID NO 4 do SEQ ID NO 12.
The phases were separated and the aqueous phase was washed with methylene chloride (50 ml) and filtered clear (Celite). 
Faze su razdvojene i vodena faza je oprana s metilen HR P930428_B1 B1 kloridom (50 ml) i bistro profiltrirana (Velite).
The reaction mixture was maintained under stirring at room temperature and in a perfectly closed system for five hours. 
Reakcijska smjesa je uz miješanje održavana na sobnoj temperaturi te u savršeno zatvorenom sustavu tijekom 5 sati.
To provide a method for manufacturing an epoxy compound or salts thereof represented by the general formula (2): 
Postupak za proizvodnju epoksi spoja ili njegove soli, prikazanog općom formulom (2):
Suction tube device (2) according to any of claims 5-7, wherein the centrifugal pump drive system (27) comprises at least one torque limiting coupling arranged to protect the electric motor(s) from the centrifugal pump (16) in case of emergency. 
Uređaj koji ima cijev za usisavanje (2) u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što pogonski sustav (27) centrifugalne pumpe ima najmanje jednu spojku za ograničavanje okretnog momenta koja je postavljena tako da ona u slučaju potrebe štiti elektromotor/elektromotore u odnosu na centrifugalnu pumpu (16).
phenyl unsubstituted or substituted with at least one group selected from a -O-C1-C4-akyl and C1-C4-alkyl; benzothiophene; 
– fenil, koji je nesupstituiran ili je supstituiran s najmanje jednom skupinom, koju se bira između -O-C1-C4-akila i C1-C4-alkila;
However, Meldonium and monobasic, dibasic as well as tribasic pharmaceutically acceptable acid salts have equal or even higher hygroscopicity than Meldonium itself. 
Međutim, meldonij i njegove monobazične, dvobazične kao također 1 trobazične farmaceutski prihvatljiv kiselinske soli imaju jednaku ili čak veću higroskopnost nego sam meldonij.
A compound which is represented by the following structure: or a pharmaceutically acceptable salt thereof, for use in the treatment of a disease or disorder which is selected from multiple myeloma, glioblastoma, and lymphoma. 
HOMO Prah x x ili njegova farmaceutski prihvatljiva sol, pri čemu se on upotrebljava u liječenju bolesti ili poremećaja koja/i je odabran/a od sljedećih: genitalno-urinarni rak, glioblastom, rak tankog crijeva i rak dojke.
a substitution mutation at 13,409,407 bp; and 
mutacije supstitucije na 13,409,407 bp; i
wherein the nucleophilic catalyst is m-toluidine. 
pri čemu je nukleofilni katalist m-toluidin.
This allows for low construction costs, and further allows the parts to be grinded and recycled for new plastics products, e.g. 
To omogućuje niske troškove konstrukcije, i nadalje omogućuje da se dijelovi usitne i recikliraju za nove plastične proizvode, npr.
providing at least one vehicle of which a plurality of data is to be identified; 
pružanje najmanje jednog vozila čije podatke treba identificirati;
A pharmaceutical composition for use in treating a neurodegenerative disease, the composition comprising: 
Farmaceutski pripravak za upotrebu u liječenju multiple skleroze, naznačen time da se pripravak sastoji od:
A pharmaceutical composition comprising: 
STABILNI FARMACEUTSKI SASTAV KOJI SADRŽI PIRIMIDIN-SULFAMID